Check 40,000+ stocks against 26 valuation models and 37 quality factors

Zentek Ltd (ZEN) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Zentek Ltd stock C$0.29, price C$0.55, that is 46.4% below the price, quality 25 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA98942X1024

Thin data Nov 10, 2026

Zentek Ltd

ZEN · V

Weakest Setup

Our calculation puts a fair price 46% below what the stock costs today.

Low debt

Mixed Growth (revenue 5y +134.2 %/yr in CAD)

Fair value C$0.2947 · Strongly overvalued

Quality 25/100

Negative free cash flow

Trails peers (1/12)

Narrow moat 10/100 · thin data

Thin data

Estimate

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range C$0.5100 – C$7.18 · fair‑value band C$0.2210 – C$0.3683 · the C$0.5500 price screens above the C$0.2947 fair value. As of Nov 10, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada.

Show moreShow less

The company develops graphene-based antimicrobial coatings under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.

It also developing aptamers and rapid detection; and graphene oxide synthesis and graphene synthesis products. In addition, the company owns a 100% interest in the Albany graphite project located in Northern Ontario, Canada.

The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Guelph, Canada.

Stock analysis

Zentek Ltd (ZEN) currently trades at C$0.5500, while our estimate is C$0.2947, 46% below the price, so the stock looks overvalued today.

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$0.2210 (bear) to C$0.3683 (bull), the price of C$0.5500 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Zentek Ltd reported revenue of C$166K in FY2026 versus C$340K in FY2022, a compound −16.4%/yr. Reported net income was −C$9.8M in FY2026.

Key figures

Market cap C$69.6M (≈ $49.1M) · EPS (TTM) C$−0.1000 · Return on equity −53.2% · Return on assets (EBIT) −48.9% (5-year average) · Operating margin −10,104% · Revenue (TTM) C$108K · Revenue growth (YoY) −95.5% · Free cash flow −C$5.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 63% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −46%, ZEN screens richer than that median.

Fair Value

Bear C$0.2210 Fair Value C$0.2947 Bull C$0.3683

Price C$0.5500 · Downside -46.4%

Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0

How much profit the company makes from its sales and capital

Quality Growth 6

Are margins and returns getting better?

Cashflow 0

Do the profits arrive as real cash?

Financial strength 55

Debt, balance sheet and risk of trouble

Investment 67

Does it invest with discipline instead of growing at any price?

Low Volatility 50

How calm the share price moves, does not count

Price momentum 1

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 2

Distance to the 52-week high, does not count

New shares 51

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 18/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

−81.0%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+31.6%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+134.2%

Start year 2021 (pandemic)

’21

’22

’23

’24

’25

’26

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−169,210.5% (2021) → −5,981.2% (2026)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss

not computed

ZEN screens overvalued: fair value 46% below the price. Compare with Intuitive Surgical, Inc →

Compare Zentek Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 25

FUTURE (revenue growth)100 · sector 40

PAST (return on equity)0 · sector 9

HEALTH (low debt)0 · sector 98

DIVIDEND (yield)0 · sector 28

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Solventum Corporation SOLV	$90.08	$131.27	+46%	vs ZEN
EssilorLuxottica Société anonyme EL	€187.60	€196.22	+5%	vs ZEN
Intuitive Surgical, Inc ISRG	$450.04	$353.90	−21%	vs ZEN
Medline Inc MDLN	$40.91	$28.59	−30%	vs ZEN
Alcon Inc ALC	CHF 61.88	CHF 34.06	−45%	vs ZEN
Becton, Dickinson and Company BDX	$212.61	$97.80	−54%	vs ZEN
Straumann Holding STMN	CHF 106.85	CHF 45.50	−57%	vs ZEN
West Pharmaceutical Services, Inc WST	$412.55	$139.22	−66%	vs ZEN
Sartorius Stedim Biotech S.A DIM	€223.40	€54.82	−75%	vs ZEN
Sartorius Aktiengesellschaft SRT	€227.00	€42.50	−81%	vs ZEN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks Stocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

Frequently asked questions

Is Zentek Ltd (ZEN) overvalued or undervalued?

As of Nov 10, 2026, our estimate of fair value is C$0.2947 versus a price of C$0.5500, about 46% lower (overvalued).

What is the fair value of ZEN?

Our estimate for Zentek Ltd is C$0.2947 (as of Nov 10, 2026), built from audited fundamentals. The current price: C$0.5500.

What is the quality score of ZEN?

Zentek Ltd has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Zentek Ltd (ZEN)?

Our calculated price target is the estimate of C$0.2947 (as of Nov 10, 2026). Cautious scenario C$0.2210, optimistic scenario C$0.3683. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.

What is the Zentek Ltd stock forecast for 2026?

Our estimate puts fair value at C$0.2947, about 46% lower versus a price of C$0.5500 (overvalued). Cautious scenario C$0.2210, optimistic scenario C$0.3683. The calculation is refreshed regularly with new filings.

What is the revenue of Zentek Ltd (ZEN)?

Zentek Ltd reported trailing-twelve-month revenue of about C$108K (latest available figure, as of Nov 10, 2026).

What is the intrinsic value of Zentek Ltd (ZEN)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zentek Ltd it is C$0.2947 per share (as of Nov 10, 2026), against a price of C$0.5500.

Is Zentek Ltd stock overvalued or undervalued in 2026?

As of Nov 10, 2026, ZEN trades above its calculated fair value: price C$0.5500, fair value C$0.2947, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of ZEN?

No. The price is what the market pays today (C$0.5500); the fair value is what the company's own numbers justify (C$0.2947). For Zentek Ltd the two are C$0.2553 per share apart. That gap is exactly why we show both numbers side by side.

How much is Zentek Ltd worth?

The market values Zentek Ltd at about C$69.6M (market capitalisation, as of Nov 10, 2026). Per share that is C$0.5500; our models calculate a fair value of C$0.2947 per share.

What do the bullish and bearish scenarios say about ZEN?

Our models span a range for Zentek Ltd: cautious scenario C$0.2210, base C$0.2947, optimistic C$0.3683 per share (as of Nov 10, 2026, price C$0.5500). The range comes from different growth and margin assumptions, not from analyst opinions.

How far is ZEN from its 52-week high?

Zentek Ltd trades at C$0.5500, about 63% below its 52-week high of C$1.50 and 8% above the low of C$0.5100 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.2947 is for.

Which stocks are comparable to Zentek Ltd?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Zentek Ltd stock attractive at the current price?

The data as of Nov 10, 2026: price C$0.5500, calculated fair value C$0.2947 (−46%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

Is it still worth investing in stocks now?

The global stock market currently sits 15.1% above its aggregate fair value. Zentek Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Zentek Ltd (ZEN)?

The closing price on Nov 10, 2026 was C$0.5500. Our estimate is C$0.2947, about 46% lower (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Zentek Ltd right now?

The price sits above even our optimistic bull case (C$0.3683). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Zentek Ltd

How large is the market capitalisation of Zentek Ltd (ZEN)?

The market capitalisation of Zentek Ltd is C$69.6M (≈ $49.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Zentek Ltd (ZEN)?

Earnings per share at Zentek Ltd are C$−0.1000. Earnings per share over the last twelve months: total profit spread across every single share.

What is the return on equity of Zentek Ltd (ZEN)?

The return on equity (ROE) of Zentek Ltd is −53.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Zentek Ltd (ZEN)?

On an EBIT basis the return on assets of Zentek Ltd is −48.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Zentek Ltd (ZEN)?

The operating margin of Zentek Ltd is −10,104% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Zentek Ltd (ZEN)?

Revenue at Zentek Ltd is growing −95.5% versus a year earlier (3y avg +31.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Zentek Ltd (ZEN) generate?

The free cash flow of Zentek Ltd is −C$5.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Zentek Ltd (ZEN) carry?

The net debt of Zentek Ltd is C$449K (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Continue in the live analysis

Fair value and trend for 40,000+ stocks, watchlist, comparison and the diversification check.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.